Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 6/20 | 0.44 |
| ▸ | RXRB | P28702 | 5/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17354676 | 1.00 | DHODH (0.49) | DHODHP2RY14EGFRRARBRARG | |
| SCHEMBL17354678 | 0.92 | P2RY14 (0.46) | DHODHP2RY14EGFRRARBRARG | |
| SCHEMBL21133397 | 0.89 | EGFR (0.55) | P2RY14EGFRRARBRARGRXRA | |
| SCHEMBL18624975 | 0.88 | EGFR (0.58) | EGFRRARBRARGRXRARXRB | |
| SCHEMBL20026783 | 0.88 | EGFR (0.58) | EGFRRARBRARGRXRARXRB | |
| SCHEMBL18604545 | 0.88 | RARB (0.50) | P2RY14RARBRARGPTPN11 | |
| SCHEMBL5667683 | 0.87 | DHODH (0.61) | DHODHP2RY14EGFRRARBRARG | |
| SCHEMBL30610351 | 0.87 | DHODH (0.57) | DHODHP2RY14EGFRRXRARXRB | |
| SCHEMBL18688872 | 0.85 | RXRA (0.53) | P2RY14EGFRRARBRARGRXRA | |
| SCHEMBL21133286 | 0.84 | EGFR (0.58) | EGFRRARBRARGRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629639-B2 | Spacer for a spiral wound membrane | EVOVE LTD (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20250188521-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. | 2025-06-12 | — | — | US | disclosed |
| US-12188088-B1 | Multiplexed targeted amplification of polynucleotides | Singular Genomics Systems, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240425919-A1 | MULTIPLEXED TARGETED AMPLIFICATION OF POLYNUCLEOTIDES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-12-26 | — | — | US | disclosed |
| EP-4422792-A1 | MULTIPLEXED TARGETED AMPLIFICATION OF POLYNUCLEOTIDES | Singular Genomics Systems, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240240251-A1 | MULTIPLEXED TARGETED AMPLIFICATION OF POLYNUCLEOTIDES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-07-18 | — | — | US | disclosed |
| EP-4397399-A2 | MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES | G2O Water Technologies Limited (GB) | 2024-07-10 | — | — | EP | disclosed |
| US-20240157304-A1 | SPACER FOR A SPIRAL WOUND MEMBRANE | EVOVE LTD (GB) | 2024-05-16 | — | — | US | disclosed |
| US-20240149223-A1 | MEMBRANE DEVICE | EVOVE LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4304765-A1 | SPACER FOR A SPIRAL WOUND MEMBRANE | Evove Ltd (GB) | 2024-01-17 | — | — | EP | disclosed |
| US-20230399692-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-12-14 | — | — | US | disclosed |
| US-11795505-B2 | Nucleic acid delivery scaffolds | Singular Genomics Systems, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230287491-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-09-14 | — | — | US | disclosed |
| WO-2023172665-A2 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023076833-A1 | MULTIPLEXED TARGETED AMPLIFICATION OF POLYNUCLEOTIDES | Singular Genomics Systems, Inc. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022189793-A1 | MEMBRANE DEVICE | EVOVE LTD (GB) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022189785-A1 | SPACER FOR A SPIRAL WOUND MEMBRANE | EVOVE LTD (GB) | 2022-09-15 | — | — | WO | disclosed |
| US-20210363619-A1 | METHOD FOR TUNING THERMAL EXPANSION PROPERTIES IN AN ADDITIVE MANUFACTURING FEEDSTOCK MATERIAL | NAT TECH & ENG SOLUTIONS SANDIA LLC (US) | 2021-11-25 | — | — | US | disclosed |
| US-11118249-B1 | Method for tuning thermal expansion properties in an additive manufacturing feedstock material | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3774001-A1 | MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES | G2O Water Technologies Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629639-B2 | Spacer for a spiral wound membrane | AQP1, AQP3, AQP4 | DHODH 2238/4885P2RY14 4474/4885EGFR 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.